Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“strategies based on the enhancement of cellular waste disposal capacity (i.e., TFEB‐TFE3 gene therapy) hold promise of preclinical benefits in these pathological scenarios (Spampanato et al, 2013; Bajaj et al, 2019).”
From Autophagy in major human diseases (2021) · cites this paper as Spampanato et al, 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605 · cited 2×
“…abnormality in PD muscle fibres – autophagic accumulation (Raben et al, 2012) – was not reproduced in PD myotubes, as demonstrated by immunostaining and western analysis with LC3 [a highly specific autophagosomal marker (Kabeya et al, 2000)] (shown for western blot in Supporting Information Fig S1C).”
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
TFEB Links Autophagy to Lysosomal Biogenesis
Settembre, C., Di Malta, C., Polito, V. A., Arencibia, M. G., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., et al. (2011) · Science · doi:10.1126/science.1204592 · Cited by 3,365 · cited 5×
“Furthermore, since TFEB has been shown to promote lysosomal– autophagosomal fusion (Settembre & Ballabio, 2011; Settembre et al, 2011), this approach, unlike most current efforts, has the potential to prevent or resolve autophagic build-up.”
InfluentialSelf-citationA Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 5×
“Plasmids: plasmid containing the full-length 3xFlag-tagged human TFEB (referred to as Flag-TFEB) was described previously (Sardiello et al, 2009); plasmid containing the full-length rat LAMP1 (mCherry-LAMP1) was obtained from Dr. Kristien Zaal (Light Imaging Section, Office of Science & Technology,…”
InfluentialSelf-citationMammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956 · cited 1×
“Defects in autophagy, a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre…”
A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.32 · Cited by 1,920
Self-citationLysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,740 · cited 1×
“Lysosomal function depends on the ability of lysosomal membranes to fuse with other vesicles’ membranes and with the plasma membrane (Luzio et al, 2007).”
Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function
Saftig, P., & Klumperman, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2745 · Cited by 1,648 · cited 1×
“LAMPs are considered to be of key importance for lysosomal movement, maturation of autophago-somes and lysosomal exocytosis (Saftig & Klumperman, 2009).”
Roczniak-Ferguson, A., Petit, C. S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,366
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
Martina, J. A., Chen, Y., Gucek, M., & Puertollano, R. (2012) · Autophagy · doi:10.4161/auto.19653 · Cited by 1,333 · cited 6×
“Next, we attempted to activate endogenous TFEB by pharmacologically targeting mTORC1, which has been shown to negatively regulate TFEB (Martina et al, 2012; RoczniakFerguson et al, 2012; Settembre et al, 2012).”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 201–300 of 342
Small molecules as therapeutic agents for inborn errors of metabolism
Matalonga, L., Gort, L., & Ribes, A. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-0005-3 · Cited by 23
“ing TFEB in different Pompe disease models (Spampanato et al. 2013).”
BackgroundIncreased mTOR Signaling and Impaired Autophagic Flux Are Hallmarks of SARS-CoV-2 Infection
Maktura, G. C., Dias, T. L., Zambalde, É. P., Brenha, B., Amorim, M. R., Santos, L. N., Buscaratti, L. I., Elston, J. G. D. A., Mara, C., Mancini, M. C. S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb45010023 · Cited by 25
Transcriptional regulation of autophagy in skeletal muscle stem cells
Krishnan, P. D. G., Lee, W. X., Goh, K. Y., Choy, S. M., Turqueza, L. R. R., Lim, Z. H., & Tang, H.-W. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052007 · Cited by 23
“Similarly, TFEB gene transfer improved skeletal muscle pathology in iPSCs derived from late-onset Pompe disease, which were induced to differentiate into skeletal muscle cells (Sato et al., 2016; Spampanato et al., 2013).”
He, L., Weber, K., Diwan, A., & Schilling, J. D. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1015-463r · Cited by 22
Zhang, Z., Guo, M. L., Zhao, S., Xu, W., Shao, J., Zhang, F., Wu, L., Lu, Y., & Zheng, S. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.06.003 · Cited by 23
Du, K., Chen, H., Pan, Z., Zhao, M., Cheng, S., Luo, Y., Zhang, W., & Li, D. (2025) · eLife · doi:10.7554/elife.103137.3 · Cited by 21
What’s new and what’s next for gene therapy in Pompe disease?
Roger, A. L., Sethi, R., Huston, M. L., Scarrow, E. R., Bao-Dai, J., Lai, E., Biswas, D. D., Haddad, L. E., Strickland, L. M., Kishnani, P. S., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2067476 · Cited by 20
Wang, P., Zhao, C., Zhou, H., Huang, X., Ying, H., Zhang, S., Pan, Y., & Zhu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511899 · Cited by 20
Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy
Colella, P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00733-x · Cited by 24
Kim, Y. R., Park, M. S., Eum, K., Kim, J., Lee, J. W., Bae, T., Lee, D. H., & Choi, J. W. (2015) · Oncotarget · doi:10.18632/oncotarget.5208 · Cited by 20
“TFs bind to specific DNA sequences and control their transcription rate [10, 11].”
James, A., Hendrixson, J. A., Kadhim, I., Marques-Carvalho, A., Laster, J., Crawford, J., Thostenson, J., Wanchai, V., Sato, A. Y., Nookaew, I., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.191688 · Cited by 20
“This approach is based on evidence that targeted overexpression of Tfeb in myotubes (13), neurons (14–16), oligodendrocytes (15), macrophages (17), cardiac myocytes (18), or chondrocytes (19) is sufficient to induce autophagy and alleviate dysfunction in murine models of Pompe disease, Parkinson…”
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia
Montanaro, A., Kitara, S., Cerretani, E., Marchesini, M., Rompietti, C., Pagliaro, L., Gherli, A., Su, A. H., Minchillo, M. L., Caputi, M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05002-5 · Cited by 19
“Because glycogen accumulation may result in disruptive autophagosomes and lysosomes formation/degradation cycle [35] we repeated the acidotropic staining in the presence or absence of 2-Deoxy-d-glucose (2-DG) to lock the activity of hexokinase and inhibit the access of glucose for glycolysis and glycogen formation.”
MethodZhang, J., He, J. N., Johnson, J. L., Napolitano, G., Ramadass, M., Rahman, F., & Catz, S. D. (2019) · Autophagy · doi:10.1080/15548627.2019.1596475 · Cited by 18
Zhang, L., Li, Z., Zhang, L., Qin, Y., & Yu, D. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115698 · Cited by 17
Wang, S., Jing, K., Wu, H.-L., Li, X., Yang, C., Li, T., Tang, H.-X., Zou, T., She, Y., & Liu, H.-F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2812493 · Cited by 18
New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System
Gigliobianco, M. R., Martino, P. D., Deng, S., Casadidio, C., & Censi, R. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708213159 · Cited by 17
Failure of Autophagy in Pompe Disease
Do, H., Meena, N. K., & Raben, N. (2024) · Biomolecules · doi:10.3390/biom14050573 · Cited by 17
“Overexpression of TFEB in mCherry-LAMP1/GFP-LC3-labeled fibers resulted in near complete elimination of autophagic buildup; importantly, this was the first indication that the buildup can be reversed [80].”
BackgroundMethodInfluentialSelf-citationActivation of Master Autophagy Regulator TFEB During Systemic LPS Administration in the Cornea
Uchida, K., Unuma, K., Funakoshi, T., Aki, T., & Uemura, K. (2014) · Journal of Toxicologic Pathology · doi:10.1293/tox.2014-0004 · Cited by 16
Farah, B. L., Madden, L. R., Li, S., Nance, S. A., Bird, A., Bursac, N., Yen, P. M., Young, S. P., & Koeberl, D. D. (2014) · The FASEB Journal · doi:10.1096/fj.13-244202 · Cited by 15
The Transcription Factor EB (TFEB) Sensitizes the Heart to Chronic Pressure Overload
Wundersitz, S., Tortola, C. P., Schmidt, S., Vidal, R. O., Kny, M., Hahn, A., Zanders, L., Katus, H. A., Sauer, S., Butter, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115943 · Cited by 17
Pharmacological approaches to tackle NCLs
Kauss, V., Dambrova, M., & Medina, D. L. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165553 · Cited by 14
Transcription factor EB as a key molecular factor in human health and its implication in diseases
Gebrie, A. (2023) · SAGE Open Medicine · doi:10.1177/20503121231157209 · Cited by 14
Perspective on innovative therapies for globoid cell leukodystrophy
Ricca, A., & Gritti, A. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23752 · Cited by 16
“…LSD (Parenti et al., 2015) aimed at enhancing storage clearance and/or implementing enzyme replacement (Raben et al., 2010; Medina et al., 2011; Spampanato et al., 2013) might be considered as complementary therapeutic targets, provided the role of these pathways in GLD pathophysiology will be…”
BackgroundDu, K., Chen, H., Pan, Z., Zhao, M., Cheng, S., Luo, Y., Zhang, W., & Li, D. (2025) · eLife · doi:10.7554/elife.103137 · Cited by 13
Pros and cons of different ways to address dysfunctional autophagy in Pompe disease
Lim, J., Meena, N. K., & Raben, N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.51 · Cited by 14
Self-citationEvaluating and modulating TFEB in the control of autophagy: toward new treatments in CNS disorders
Costa, A. D., Metais, T., Mouthon, F., Kerkovich, D. M., & Charvériat, M. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12634 · Cited by 15
Methods to Monitor and Manipulate TFEB Activity During Autophagy
Medina, D. L., Settembre, C., & Ballabio, A. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.10.008 · Cited by 14
Self-citationMaeda, M., Seto, T., Kadono, C., Morimoto, H., Kida, S., Suga, M., Nakamura, M., Kataoka, Y., Hamazaki, T., & Shintaku, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235829 · Cited by 13
“Conversely, overexpression of the autophagy-stimulating gene transcription factor EB also suppressed signs in a mouse model of Pompe disease [12].”
BackgroundShammas, H., Fog, C. K., Klein, P., Koustrup, A., Pedersen, M. T., Bie, A. S., Mickle, T. C., Petersen, N. H. T., Jensen, T. K., & Guenther, S. M. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109103 · Cited by 14
Plasma membrane remodeling in GM2 gangliosidoses drives synaptic dysfunction
Nicholson, A. S., Priestman, D. A., Antrobus, R., Williamson, J. C., Bush, R., McKie, S. J., Barrow, H. G., Smith, E., Dobrenis, K., Bright, N. A., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003265 · Cited by 12
“Enhancement of lysosomal exocytosis has been explored as a method to ameliorate the effects of LSDs via chemical induction, using cyclodextrin, or induced TFEB expression [120,121].”
657PLysosomal damage in Duchenne muscular dystrophy: an emerging therapeutic target
Jaber, A., Palmieri, L., Bakour, R., Lachiver, E., Hong, A. V., Bourg, N., Pupiot, J., Poupiot, J., Stokholm, D., van Wittenberghe, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv6805 · Cited by 12
“In this context, overactivation of TFEB can rescue the autophagic block ( 64 ), suggesting that defective lysosomal function—rather than mTOR signaling alone—may underlie impaired autophagic flux.”
Vicencio, E., Nuñez-Belmar, J., Cárdenas, J. P., Cortés, B. I., Martín, A. J. M., Maracaja‐Coutinho, V., Rojas, A., Cafferata, E. A., González, L., Vernal, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914835 · Cited by 13
“TFEB has emerged as a therapeutic modulator in lysosomal storage diseases [90,91] and a promising target in the treatment of neurodegenerative disorders (ND), such as Alzheimer’s disease and Parkinson’s diseases [92,93].”
BackgroundZhang, X., Liu, H., Meena, N. K., Li, C., Zong, G., Raben, N., Puertollano, R., & Wang, L. (2021) · Chemical Science · doi:10.1039/d1sc03188k · Cited by 12
Self-citationUnraveling Lysosomal Exocytosis: From Molecular Mechanisms to Physiological Functions
Jiang, S., Fu, J., Li, S., Li, Z., Zhao, Q., Yin, Y., Yang, M., & Wang, Y. (2025) · Traffic · doi:10.1111/tra.70026 · Cited by 12
“TFEB overexpression in a mouse model of Pompe disease, characterized by acid α-glucosidase (GAA) deficiency and glycogen accumulation, induces lysosomal autophagy and autolysosome exocytosis to ease the glycogen burden [151].”
Lysosome pH Dynamics in Physiology and Disease: Molecular Mechanisms and Therapeutic Insights
Infante-Tadeo, S., & Barber, D. L. (2026) · Acta Physiologica · doi:10.1111/apha.70160 · Cited by 12
“Decreased pHlys has been documented in mucolipidosis type IV (MLIV) [83, 150, 151] and Pompe disease [152].”
Hou, W. C., Massey, L. A., Rhoades, D. J., Wu, Y., Ren, W., Frank, C., Overkleeft, H. S., & Kelly, J. W. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320257121 · Cited by 11
“…the transcription factor TFE3, has also been shown to regulate lysosomal genes and functions similarly to TFEB by also binding to the CLEAR element (35); therefore, focusing on TFEB as the sole activator of GCase in the context of autophagy could understate the involvement of other MiT/TFE family…”
Nociari, M., Kiss, S., & Rodriguez-Boulan, E. J. (2017) · InTech eBooks · doi:10.5772/intechopen.69304 · Cited by 16
L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation
Castejón‐Vega, B., Lendines‐Cordero, D., Rubio, A., Pérez‐Pulido, A. J., Bullón, P., Quiles, J. L., Lane, J. D., Domínguez, B. F., Cachón-González, M. B., Martin-Ruiz, C. M., et al. (2021) · Cells · doi:10.3390/cells10113122 · Cited by 12
“The pathological changes, with abundant multilamellar bodies, closely resemble those first reported in neurons obtained from the brains of infants with Tay–Sachs disease [10].”
BackgroundAutophagy at the crossroads of metabolism and cellular defense
Begun, J., & Xavier, R. J. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328365d34d · Cited by 10
Lysosomal ATP Transporter SLC17A9 Controls Cell Viability via Regulating Cathepsin D
Huang, P., Cao, Q., Xu, M., & Dong, X. (2022) · Cells · doi:10.3390/cells11050887 · Cited by 11
Jia, X., Shao, L., Liu, C., Chen, T., Peng, L., Cao, Y., Zhang, C., Yang, X., Zhang, G., Gao, J., et al. (2020) · Aging · doi:10.18632/aging.102879 · Cited by 11
“2446G>A also has a higher allele mutation frequency in the population [4, 18, 19].”
BackgroundTFEB overexpression alleviates autophagy-lysosomal deficits caused by progranulin insufficiency
Nader, W. O., Brown, K. S., Boyle, N. R., Kaplelach, A. K., Abdelaziz, S. M., Davis, S. E., Aljabi, Q., Hakim, A. R., Davidson, A. G., Vollmer, G. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-12268-0 · Cited by 10
“Lysosomal exocytosis may be another mechanism by which TFEB overexpression reduced storage material in Grn –/– mice, as TFEB-mediated clearance of storage material in models of other lysosomal storage disorders has been associated with increased lysosomal exocytosis 51,52 .”
Liang, Q., Vlaar, E. C., Pijnenburg, J. M., Rijkers, E., Demmers, J., Vulto, A. G., van der Ploeg, A. T., van Til, N. P., & Pijnappel, W. W. M. P. (2023) · Journal of Proteomics · doi:10.1016/j.jprot.2023.105037 · Cited by 9
Bastien, J., Menon, S., Messa, M., & Nyfeler, B. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101018 · Cited by 10
A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders
Hegeman, C. V., de Jong, O. G., & Lorenowicz, M. J. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.41 · Cited by 9
Revisiting regulatory coherence: accounting for temporal bias in plant gene co‐expression analyses
Cai, H., & Marais, D. L. D. (2023) · New Phytologist · doi:10.1111/nph.18720 · Cited by 10
Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1
Castiblanco, D., Rudd-Schmidt, J. A., Noori, T., Sutton, V. R., Hung, Y. H., Flinsenberg, T. W. H., Hodel, A. W., Young, N. D., Smith, N. J. C., Bratkovic, D., et al. (2022) · Blood · doi:10.1182/blood.2021013477 · Cited by 12
TRPML1 and TFEB, an Intimate Affair
Medina, D. L. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_603 · Cited by 9
Pu, N., Li, S., Wu, H., Zhao, N., Wang, K., Dong, W., Wang, J., Sha, L., Zhao, Y., Tao, Y., et al. (2025) · Antioxidants · doi:10.3390/antiox14050561 · Cited by 9
“The Que/mR150-NSLNs had a particle size of 209 nm and a DEE of 85.25 ± 1.29%.”
InfluentialToward Systemic Lipofuscin Removal
Renteln, M. (2024) · Rejuvenation Research · doi:10.1089/rej.2024.0034 · Cited by 9
“105 Also, extraction from the peritoneal space would perhaps be easiest initially, as deschloroclozapine 93,94 is BBB-permeable and can be slowly released from biodegradable beads placed there laparoscopically.”
Zhang, T., Zhang, R., Liu, W. C., Qi, Y., Wang, H., Zhang, H., Xiao, Z. J., Pandol, S. J., Han, Y., & Zheng, X. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167065 · Cited by 9
Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat
Mele, B. H., Rossetti, F., Cubellis, M. V., Monticelli, M., & Andreotti, G. (2024) · Genes · doi:10.3390/genes15030290 · Cited by 7
Jin, J., Chen, Y., Chen, X., Zhang, Z., Wu, Y., Tian, N., Wu, A., Wang, X., Shao, Z., Zhou, Y., et al. (2024) · The Spine Journal · doi:10.1016/j.spinee.2024.10.018 · Cited by 7
Drug induced exocytosis of glycogen in Pompe disease
Turner, C. T., Fuller, M., Hopwood, J. J., Meikle, P. J., & Brooks, D. A. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.145 · Cited by 7
Kimura, T., Hayama, Y., Okuzaki, D., Nada, S., & Okada, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101744 · Cited by 8
“Recently, researchers have proposed that LSDs can be treated by inducing the activation of TFEB (16, 17).”
BackgroundNetting, D. J., López‐Haber, C., Hutchins, Z., Martina, J. A., Puertollano, R., & Mantegazza, A. R. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2511539122 · Cited by 6
“As current strategies for the treatment of H syndrome include anti - inflammatory agents ( 89 , 107 ), our findings suggest that modulation of autophagy or TFEB activity could also be considered to control inflammation in H syndrome, as proposed for other lysosomal storage disorders ( 108 , 109 ).”
Self-citationFrom Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease
Sánchez-Porras, V., Guevara, J., & Echeverri-Peña, O. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512481 · Cited by 6
“Both TFEB and TFE3 (transcription factor E3) have been contemplated as therapeutic targets for PD because they promote lysosomal exocytosis and decrease glycogen accumulation [8,41,42].”
BackgroundAguilar-González, A., González-Correa, J. E., Barriocanal‐Casado, E., Ramos-Hernández, I., Lerma-Juárez, M. A., Greco, S., Rodríguez‐Sevilla, J. J., Molina-Estévez, F. J., Montalvo-Romeral, V., Ronzitti, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116298 · Cited by 6
“There are several in vitro murine cellular models available [31,36,49]; unfortunately, they do not fully mimic severe IOPD signatures or LOPD disease progression.”
BackgroundGlycogen Exocytosis from Cultured Pompe Skin Fibroblasts
Turner, C. T., & Fuller, M. (2015) · Translational Biomedicine · doi:10.21767/2172-0479.100017 · Cited by 6
Krag, T. O. B., Holm-Yildiz, S. D., Witting, N., & Vissing, J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01212-8 · Cited by 6
“For Pompe disease, activation of TFEB has been suggested as a therapeutic target in order to increase the availability of autophagy-related proteins, and thus increase processing of intracellular waste and lysosomal content [42].”
BackgroundProspects for Stem Cell Therapy in Neuronal Ceroid Lipofuscinosis
Kruer, M. C., Pearce, D. A., Orchard, P. J., & Steiner, R. D. (2013) · Regenerative Medicine · doi:10.2217/rme.13.46 · Cited by 6
“Aberrant or mislocalized protein or lipid may lead to storage [12] or excretion [13] from the cell in non-traditional ways, perhaps as a means to try to protect the cell from toxic accumulation.”
BackgroundManthe, R. L., Rappaport, J. A., Long, Y., Solomon, M. A., Veluvolu, V. D., Hildreth, M. B., Gugutkov, D., Marugán, J., Zheng, W., & Muro, S. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257345 · Cited by 6
“…diseased lysosomes to the extracellular milieu, where they can be removed by the lymphatics, the immune system, etc. (Klein et al., 2005; Chen et al., 2010; Strauss et al., 2010; Medina et al., 2011; Xu et al., 2012; Spampanato et al., 2013; Cao et al., 2015; Long et al., 2016; Zhong et al., 2016).”
BackgroundInfluentialGAA deficiency promotes angiogenesis through upregulation of Rac1 induced by autophagy disorder
Li, Z., Li, B., Wang, J., Lu, Y., Chen, A. F. Y., Sun, K., Yu, Y., & Chen, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118969 · Cited by 6
Biological biomarkers in muscle diseases relevant for follow-up and evaluation of treatment
Stemmerik, M. P. G., Tasca, G. A., Gilhus, N. E., Servais, L., Vicino, A., Maggi, L., Sansone, V., & Vissing, J. (2024) · Brain · doi:10.1093/brain/awae323 · Cited by 6
Galectin-3: a novel biomarker of glycogen storage disease type III
Rossiaud, L., Miagoux, Q., Benabidès, M., Reiss, O., Jauze, L., Jarrige, M., Polvèche, H., Malfatti, E., Laforêt, P., Ronzitti, G., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02452-6 · Cited by 5
“GSDIII Patient2 , GSDIII Patient3 , and GSDIII Patient4 hiPSC lines were reprogrammed with the Sendaï virus technique at IStem from GSDIII patient fi broblasts (GM3390, GM0303, GM2523) provided by Coriell Institute (Camden, NJ, United States) [34].”
Autophagy in cancer and protein conformational disorders
Attanasio, S. (2025) · FEBS Letters · doi:10.1002/1873-3468.70061 · Cited by 5
“Importantly, gene transfer of TFEB decreased glycogen storage and excess accumulation of autophagosomes in a mouse model of Pompe disease, a lysosomal storage disorder [215].”
Survival of intracellular pathogens in response to mTORC1- or TRPML1-TFEB-induced xenophagy
Capurro, M., Prashar, A., Gao, X., & Jones, N. L. (2023) · Autophagy Reports · doi:10.1080/27694127.2023.2191918 · Cited by 5
Autophagic cell death in viral infection: Do TAM receptors play a role?
Datan, E., & Salman, S. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.10.001 · Cited by 5
Lysosomes and the pathogenesis of merosin-deficient congenital muscular dystrophy
Smith, S. J., Fabian, L., Sheikh, A., Noche, R. R., Cui, X., Moore, S. A., & Dowling, J. J. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab278 · Cited by 7
Cardiac dysfunction and altered gene expression in acid ceramidase-deficient mice
Kleynerman, A., Rybová, J., McKillop, W. M., Dlugi, T. A., Faber, M. L., Fuller, M., O'Meara, C. C., & Medin, J. A. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00289.2024 · Cited by 4
Mierke, C. T. (2020) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-030-58532-7_9 · Cited by 3
Murray, A. K. (2020) · Biomolecules · doi:10.3390/biom10121613 · Cited by 3
“This has been shown for the export of stored glycogen from Pompe mouse cells in culture [26,27] and for the release of lysosomal enzymes in urine [28].”
BackgroundHannah, W. B., Case, L. E., Smith, E. C., Walters, C. K., Bali, D. S., Kishnani, P. S., & Koeberl, D. D. (2023) · JIMD Reports · doi:10.1002/jmd2.12391 · Cited by 3
The Roles of Lysosomal Exocytosis in Regulated Myelination
Chen, G. (2016) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2016/5.1047 · Cited by 3
Golgi requires a new casting in the screenplay of mucopolysaccharidosis II cytopathology
Molnár, K., Kobolák, J., & Dinnyés, A. (2021) · Biologia Futura · doi:10.1007/s42977-021-00107-y · Cited by 3
Cox, T. M. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0002270.pub2 · Cited by 3
Severa, G., Bastu, S., Borin, G. U., Decrouy, X., Codina, A., Kefi, K., Periou, B., Nadaj‐Pakleza, A., Lannes, B., Sacconi, S., et al. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf083 · Cited by 2
Paidi, R. K., Gorai, S., Mondal, S., & Pahan, K. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70432 · Cited by 2
Sharshakova, A., Fattakhova, А. А., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Kutovoi, G. I., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083703 · Cited by 2
TFEB, Master Regulator of Cellular Clearance
Diez‐Roux, G., & Ballabio, A. (2016) · Wiley eBooks · doi:10.1002/9781118978320.ch7 · Cited by 2
Self-citationTRPML1-Dependent Processes as Therapeutic Targets
Venkatachalam, K., & Kiselyov, K. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420024-1.00025-4 · Cited by 2
Autophagy Enhancers, are we there Yet?
Lu, S., & Nixon, R. A. (2016) · Wiley eBooks · doi:10.1002/9781118978320.ch14 · Cited by 2
Neurodegenerative Diseases and Autophagy
Fleming, A., Vicinanza, M., Renna, M., Puri, C., Ricketts, T., Füllgrabe, J., López, A., de Jager, S., Ashkenazi, A., Tanasa, M. P., et al. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00011-0 · Cited by 4
“…al., 2011) has a prominent role, as its overexpression alone is sufficient to induce autophagy and to ameliorate the phenotype of neurodegenerative diseases (Decressac et al., 2013; Tsunemi et al., 2012) and lysosomal storage disorders (LSDs) in vivo (Medina et al., 2011; Spampanato et al., 2013).”
BackgroundCa2+-Dependent Regulation of TFEB and Lysosomal Function
Paola, S. D., & Medina, D. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9018-4_13 · Cited by 2
Du, K., Chen, H., Pan, Z., Zhao, M., Cheng, S., Luo, Y., Zhang, W., & Li, D. (2025) · eLife · doi:10.7554/elife.103137.2 · Cited by 2
Autophagic and Lysosomal Disorders
Chandra, S., & Pahan, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_11 · Cited by 1
Organellar crosstalk as a potential therapeutic target for rare neurodegenerative diseases
Lam, J., Li, C., Terluk, M. R., & Kartha, R. V. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2024.55 · Cited by 1
Cocchiararo, I., & Castets, P. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251314767 · Cited by 1
“142 Of note, inhibition of autophagy induction by targeting Atg5 / Atg7 increased the bene fi ts of the enzyme replacement strategy in mouse models of Pompe disease.”
Pharmacotherapy of Pompe disease
Parenti, G., & Andria, G. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.795855 · Cited by 1
“The potential of TFEB-mediated clearance of glycogen in PD was evaluated in muscle cell culture system and in the mouse model of the disease [103].”
BackgroundSelf-citationAutophagic Dysfunction in Gaucher Disease and its Rescue by Cathepsin B and D Proteases
Motta, M., Tatti, M., & Salvioli, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405529-2.00009-3 · Cited by 1
Exocytotic vesicle fusion classification for early disease diagnosis using a mobile GPU microsystem
Szczęsny, S., & Pietrzak, P. (2021) · Neural Computing and Applications · doi:10.1007/s00521-021-06676-2 · Cited by 1
“11, 12 and 13.”
BackgroundLysosomal Storage Diseases: Natural Products Inducing Autophagy
Chandarana, C. V., Habshi, T., Soni, A., & Acharya, S. R. (2023) · Current Drug Therapy · doi:10.2174/1574885519666230915103100 · Cited by 1
Brijmohan, A. S. (2017) · TSpace (University of Toronto) · Cited by 2
Pietrocola, F. (2015) · theses.fr (ABES) · doi:10.70675/42d6808dzc206z4e0fzb806z29f806b2f781 · Cited by 2
Hale, A. N. (2014) · UKnowledge (University of Kentucky)
TRATAMENTO DA DOENÇA DE POMPE - DEFICIÊNCIA DA ALFA-GLICOSIDASE ÁCIDA
Kuhn, M. I., Borges, V., & Bock, P. M. (2014) · Infarma - Ciências Farmacêuticas · doi:10.14450/2318-9312.v26.e3.a2014.pp179-187
Interrogating conserved elements of diseases using Boolean combinations of orthologous phenotypesPreprint
Woods, J. O., Tien, M. Z., & Marcotte, E. M. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/017947
“Over-expression of TFEB relieves Pompe disease, a disability of heart and skeletal muscles, by stimulating autophagy [36].”
BackgroundLysosomal pH and the Control of Genes Involved in Inflammation and Degradation
Khan, S. A. (2013) · ScholarlyCommons (University of Pennsylvania)
Characterization of Nedd4 Function and its Interaction with Angiomotin
Nath, M. (2014) · TSpace (University of Toronto)
Metadata
- Authors
- Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., Ballabio, A., & Raben, N.
- Affiliations
- Baylor College of Medicine (US)
- National Institutes of Health (US)
- Telethon Institute Of Genetics And Medicine (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Ballabio, Andrea
- Raben, Nina
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-04-18
- Volume
- 5
- Issue
- 5
- Pages
- 691-706
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3662313
- OpenAlex
- W2113698463
- Cited by
- 341
- References
- 68
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 23 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 29 · 2019: 37 · 2018: 22 · 2017: 22 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 10
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Beyond Batten Disease Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS078072)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- FP7 Ideas: European Research Council (250154)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- TFEB, Pompe disease, lysosomal storage disease, autophagy, lysosomal exocytosis, acid alpha-glucosidase deficiency, skeletal muscle, therapeutic target, lysosomal dysfunction
- MeSH terms
- Adenoviridae, alpha-Glucosidases, Animals, Autophagy, Cells, Cultured, Disease Models, Animal, Exocytosis, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Lysosomes, Mice, Knockout, Muscle, Skeletal, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.